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Despite FDA approval and CE marking of commercial tests, manufacturer-independent testing of the
technical aspects of newly developed tests is important. To evaluate the analytical performance and explore the
clinical applicability of the new Roche COBAS AmpliPrep COBAS TaqMan HIV-1 test, version 2.0 (CAP/CTM
v2.0), platform comparison was performed with the Roche CAP/CTM test, version 2.0, the COBAS Amplicor
HIV-1 Monitor Test, version 1.5 (CAP/CA v1.5), the COBAS AmpliPrep COBAS TaqMan HIV-1 Test (CAP/
CTM v1.0), and the Abbott m2000 RealTime HIV-1 assay on panels and diagnostic samples. Specificity was
tested for HIV-2 samples. Furthermore, samples from HIV-1-seropositive individuals with CAP/CA v1.5-
measured viral loads below 50 HIV-1 RNA copies per ml (cp/ml) and replicates of HIV-1-seronegative plasma
were tested in a checkerboard analysis. CAP/CTM v2.0 is HIV-1 specific, with broad genotype inclusivity and
no serious underquantification of viral load relative to the other assays used. Low viral loads below the
threshold of quantification for CAP/CA v1.5 are observed with CAP/CTM v2.0. A CAP/CTM v2.0-measured
viral load of >50 copies/ml in these samples correlated with therapy failure. In conclusion, CAP/CTM v2.0 is
an accurate and reliable test for HIV-1 viral load measurement relative to the other assays used with respect
to specificity, sensitivity, and genotype inclusivity.
HIV-1 is a major cause of morbidity and mortality in both
the developing and the developed world. Relatively effective
therapies have been readily available in developed countries
for quite some time, and measurement of HIV-1 viral load is
an important parameter in patient management both before
initiation and during therapy (2).
The first assays described for determining HIV-1 viral load
in plasma were based on target amplification techniques, like
reverse transcriptase PCR (RT-PCR) and nucleic acid se-
quence-based amplification (NASBA) with readouts on aga-
rose gel or with biotinylated primers and enzymatic detection
of the amplicon (1, 3, 11, 15). Subsequently, signal amplifica-
tion techniques were developed for quantitative detection of
HIV-1 RNA (5). The suppliers of non-real-time detection sys-
tems at the moment are, among others, Roche (COBAS Am-
plicor Monitor), Abbott (LcX for RT-PCR based systems),
bioMe´rieux (with a NASBA-based technique), and Siemens
(with the Versant HIV-1 RNA [bDNA] signal amplification
technique) (4, 16). Each technique has its own advantages and
disadvantages. Relatively small dynamic range is a disadvan-
tage that all these assay formats have in common. In addition,
they are also rather sensitive to contamination, especially at
the lower limit of detection (LLOD) (19). Handling of the
samples after target amplification is a major cause of contam-
ination for NASBA- and RT-PCR-based techniques. Recently,
amplification techniques that allow real-time detection of the
amplicon have been developed for NASBA and RT-PCR,
making postamplification processing obsolete (8, 19). A seri-
ous drawback of most real-time techniques involves amplifica-
tion with target-specific oligonucleotides and detection with am-
plicon specific fluorescence-labeled probes and their sensitivity to
point mutations within primer/probe target sequences. This is
especially of concern with highly variable targets like HIV-1.
Roche has recently obtained a CE mark and received FDA
approval for a HIV-1 viral load assay (COBAS AmpliPrep CO-
BAS TaqMan HIV-1 Test, version 1.0 [CAP/CTM v1.0]) using
the COBAS TaqMan platform (17). The major drawbacks re-
ported in the literature for the first version are limited specificity
(e.g., genotype inclusivity) and a significant increase in low posi-
tive results for individuals with levels below the threshold of quan-
tification for the COBAS Amplicor HIV-1 Monitor Test, version
1.5 (CAP/CA v1.5) (6, 12–14, 22, 23). To improve the genotype
inclusivity, Roche has changed its CAP/CTM v1.0 assay by devel-
oping a dual-target assay, the COBAS AmpliPrep COBAS Taq-
Man HIV-1 Test, version 2.0 (CAP/CTM v2.0). We decided to
generate manufacturer-independent data on the performance of
the new CAP/CTM v2.0 HIV-1 viral load assay, with special
emphasis on its applicability for clinical diagnostics.
MATERIALS AND METHODS
Patient materials and quality control materials. 500 HIV-1 EDTA plasma
samples from HIV-1-seropositive patients visiting our outpatient clinic and hav-
* Corresponding author. Mailing address: Erasmus MC, Depart-
ment of Virology, ’s Gravendijkwal 230, 3015 CE Rotterdam, Neth-
erlands. Phone: (31)-10-7033431. Fax: (31)-10-7033441. E-mail: m
.schutten@erasmusmc.nl.
 Published ahead of print on 17 February 2010.
† The authors have paid a fee to allow immediate free access to this
article.
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ing HIV-1 viral loads of more than 5.0  102 copies per milliliter (cp/ml) as
determined with CAP/CA v1.5 were obtained for test comparison. In addition,
three HIV-seropositive plasma samples that were known to be underquantified
by more than 1 log10 cp/ml by CAP/CTM v1.0 were included. Samples were
stored at 80°C until use. For analysis, samples were diluted (1:10) with a pool
of HIV-1-seronegative and HIV-1 RNA-negative EDTA plasma and subse-
quently aliquoted into six ampoules and stored at 80°C until use. Dilution and
aliquoting of samples were performed with a CAS-4200 (Qiagen, Hilden, Ger-
many) to minimize pipetting errors. In addition, 502 plasma samples from pa-
tients on antiretroviral therapy (ART) and with HIV-1 viral loads of less than
5.0  101 cp/ml as determined with CAP/CA v1.5 were tested in a checkerboard
analysis with 500 replicates of an EDTA plasma pool from HIV-1-seronegative
and HIV-1 RNA-negative donors. Information regarding the use of nonnucleo-
side analogue reverse transcriptase inhibitors (NNRTI) versus protease inhibi-
tors (PI) was taken from the hospital records. The WHO international standard
(97/650) and the WHO 1st international reference genotype panel (01/466) (9,
10) were used for evaluation purposes.
HIV viral load assays. The CAP/CA v1.5, CAP/CTM v1.0, and CAP/CTM
v2.0 tests and the Abbott real-time HIV-1 viral load assay were performed
according to the manufacturer’s instructions. In summary, for the COBAS
TaqMan assays, HIV-1 RNA was isolated with the COBAS AmpliPrep ex-
traction system. For the CAP/CA v1.5 (dynamic range, 5.0E1 to 1.0E6
cp/ml) assay, eluates were manually mixed with MasterMix and viral load
measurement was performed with the COBAS Amplicor system. For the
CAP/CTM assays (CAP/CTM v1.0 [dynamic range, 4.0E1 to 1.0E7]
and CAP/CTM v2.0 [dynamic range, 2.0E1 to 1.0E7]), a docked version of
the CAP/CTM system was used. For the Abbott assay, the M2000SP/
M2000RT system was used (dynamic range, 4.0E1 to 1.0E7). An in-house-
developed assay was used for HIV-2 viral load determination essentially as
described previously, using the HIV2LTRfpr2 forward primer (5-GGAGA
GGCTGGCAGATTGAG-3), 40 pmol HIV2LTRrpr2 reverse primer (5-G
GTGAGAGTCTAGCAGGGAACAC-3), and 7 pmol HIV2LTRprb2 probe
(5-6-carboxyfluorescein [FAM]-TGGGAGGTTCTCTCCAGCACTAGCAG
G-6-carboxytetramethylrhodamine [TAMRA]-3) (21).
HIV-1 genotyping. Immediately after RNA isolation, cDNA was synthesized
using eluates (including beads) of the CAP/CA v1.5 isolation procedure. Fifteen
microliters of eluate was used in a 25-l reaction mixture containing 1 AMV
RT buffer (Promega, Leiden, Netherlands), 50 pmol HIV_v1.5_rpr1 (5-GAGG
GGTCGYTGCCAAAGAGTG-3), 0.4 mM deoxynucleoside triphosphates
(dNTPs), 500 units AMV reverse transcriptase (Promega, Leiden, Netherlands),
and 5,000 units of RNasin (Promega). cDNA synthesis was performed for 5 min
at 48°C, followed by 6 cycles of 90 s each at 49C° to 54°C, with a temperature
increase of 1°C after each cycle, and then for 105 min at 55°C, followed by a hold
at 4°C in a Minicycler (Bio-Rad Laboratories BV, Veenendaal, Netherlands).
Five microliters of cDNA was amplified in a 100-l reaction mixture contain-
ing 1 GeneAmp PCR buffer II (Applied Biosystems, Nieuwerkerk a/d IJssel,
Netherlands), 2.5 mM MgCl2, dNTPplus (0.2 mM dATP, dCTP, dGTP, and 0.6
mM dUTP; Roche Applied Science, Almere, Netherlands), and 25 pmol of
GAG-specific primer HIV1_v1.5_fpr3 (5-TAGTATGGGCAAGCAGGGAG-
3). The resulting PCR product was run on a 2% agarose gel stained with
ethidium bromide. If no gel band was visible, an additional round of nested PCR
was performed using the same mixture as described above, but with 5 l of the
first PCR product and 25 pmol of nested primers (HIV1_v1.5_fpr2 [5-GGAA
GAAGGGCTGTTGGAAATGTGG-3] and HIV1_v1.5_rpr2 [5-TCGTTGCC
AAAGAGTGATCTGAGGG-3]). If the nested PCR was negative, 5 l of cDNA
was amplified in a 50-l mixture containing 1 PCR buffer (Qiagen, Venlo, Neth-
erlands), 5 mM MgCl2, dNTPplus (0.2 mM dATP, dCTP, and dGTP and 0.6 mM
dUTP; Roche Applied Science), 2.5 units of Hotstart Taq Polymerase (Qiagen), 30
pmol of a combination of two forward primers (HIVgagfpr1m [5-ATGATGWC
AGCATGTCAGGGAGTGGG-3]), and 20 pmol of HIV1_v1.5_rpr1. The PCR
conditions were 15 min at 95°C for initial denaturation and 40 PCR cycles with 1 min
at 95°C for denaturation, 1 min at 52°C for annealing, and 1 min at 72°C for
elongation per cycle. If no PCR product was seen on a 2% agarose gel, a nested PCR
was performed using the Qiagen PCR mixture in combination with the nested
primers and the same cycling conditions as described above.
For positive amplification products, Sanger sequencing was performed with a
20-l reaction mixture, using 5 pmol of the same primers as used for PCR, 4 l
of Dye Terminator v3.1 (Applied Biosystems), 4 l of 5 sequencing buffer
(Applied Biosystems), and 1 l of PCR product. Sequences were read with an
ABI 3100 genetic analyzer. Data were collected with data collection software
(version 1.1; Applied Biosystems). Sequences were analyzed using Lasergene
version 7.2 (DNAstar, Madison, WI) and genotyped using the REGA HIV
subtyping database engine and the NCBI database engine against pure subtypes.
Sequences with bootstrap values of 70.0 were accepted.
Data analysis. Data were analyzed using Microsoft Office Excel 2003 and
SigmaPlot for Windows, version 10.0. In the platform comparison, samples with
viral loads above the quantification limit for CAP/CA v1.5 (18 samples) were
assigned a value of 1.0  105 cp/ml and samples with viral loads below the
quantification limit for any of the assays used were assigned a value comparable
to the lower limit of that assay.
RESULTS
Testing dUTP/UNG activity of CAP/CTM v2.0. Significant
increases in number of HIV-1 viral loads near the lower limit
of detection (LLOD) were observed after CAP/CA v1.5 was
switched to CAP/CTM v1.0 in centers testing HIV-1-seropos-
itive patients (6, 13, 14, 22). We investigated whether similar
results can be expected with the CAP/CTM v2.0 test and
whether these results are HIV-1 specific results, test abnormal-
ities, or false-positive results due to contamination. We first
investigated whether contamination with CAP/CA v1.5 ampli-
cons could generate false-positive results in the CAP/CTM
v2.0 test. We therefore generated a CAP/CA v1.5 amplicon in
a reaction mixture with dTTP and without dUTP from a sub-
type B-infected HIV-1 patient with a 100% conserved se-
quence relative to the CAP/CA v1.5 primers (Fig. 1). Titration
of the amplicon resulted in a standard curve with a slope of
approximately 3.3, showing that the CAP/CA v1.5 amplicon
overlaps CAP/CTM v2.0. Next, we compared the uracil-N-
glycosylase (UNG) efficiency of CAP/CTM v2.0 versus that of
CAP/CA v1.5 by titrating a known concentration of a dUTP-
containing CAP/CA v1.5 amplicon. The CAP/CTM v2.0 UNG
system proved to work slightly more efficient than the CAP/CA
v1.5 UNG system (Fig. 1), which suggests that it is unlikely that
low positive results for the CAP/CTM v2.0 assay can be attrib-
uted to contamination by CAP/CA v1.5 amplicons, since false-
positive results for CAP/CA v1.5 have so far not been an issue.
Testing the specificity of CAP/CTM v2.0. Out of 502 HIV-
1-seropositive samples showing less than 50 cp/ml with
CAP/CA v1.5, 393 samples gave identical results when an-
FIG. 1. Viral load as measured with CAP/CA v1.5 (triangles),
CAP/CTM v1.0 (squares), and CAP/CTM v2.0 of dTTP (circles) and
dUTP (diamonds) containing CAP/CA v1.5 amplicons, plotted against
the amount of input amplicon as measured with a semiquantitative
real-time RT-PCR specific for CAP/CA v1.5 amplicons.
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alyzed with CAP/CTM v2.0, but in 109 samples, more than
50 cp/ml were detected. None of the 500 HIV-1-seronega-
tive samples proved to have a viral load above the lower
limit of detection with CAP/CTM v2.0. The average and
median HIV-1 RNA loads of the samples that were positive
as determined with CAP/CTM v2.0 were 187 and 92 cp/ml,
respectively, with a standard deviation of 313 cp/ml and a
range between 51 and 2,600 copies per ml. The numbers of
months that patients showed fewer than 5.0  101 cp/ml as
determined with CAP/CA v1.5 after initiation of antiretro-
viral therapy were calculated using the date of the last
known positive HIV-1 test result and the date of collection
of the HIV-1 RNA-negative sample used in this analysis.
Zero months was taken as the value for patients with viral
loads above 5.0  101 copies per ml as determined with
CAP/CA v1.5 prior to testing of the sample with CAP/CTM
v2.0. Patients who did not have a previous follow-up sample
in our center were excluded from this analysis. The viral
load measured with CAP/CTM v2.0 was plotted against the
number of months that patients showed fewer than 50 cp/ml
of HIV-1 RNA as determined with CAP/CA v1.5 (Fig. 2).
Under antiretroviral therapy (ART), the median viral load
slowly declined over time (at 12 months, 101 records at
129 cp/ml; at 12 to 24 months, 69 records, with a median of
100 cp/ml; at 24 to 36 months, 66 records, with a median of
85 cp/ml; at 36 to 48 months, 65 records, with a median of 60
cp/ml; and at 48 months, 208 records, with a median of 78
cp/ml). After 24 months of ART, the standard deviation of
the viral load measurement decreased notably (at 12
months, 485 cp/ml; at 12 to 24 months, 608 cp/ml; at 24
to 36 months, 161 cp/ml; at 36 to 48 months,  32 cp/ml;
and at 48 months, 49 cp/ml), but the percentage of
CAP/CTM v2.0-positive samples in each quartile remained
fairly similar at around 20%. When a 1-month moving av-
erage with windows of 5, 11, and 17 months was calculated,
a steady decline in mean viral load was measured with CAP/
CTM v2.0 until 31 months after the start of therapy, after
which no further decline was observed (data not shown). A
viral load above 20 cp/ml as determined with CAP/CTM v2.0
was highly significantly correlated with a positive signal be-
low the quantification limit for CAP/CA v1.5 (Fisher’s exact
test; P 	 1.553  107). Therapy failure, as evidenced by a
CAP/CA v1.5-measured viral load above 500 cp/ml or two
subsequent measurements above 50 cp/ml, was determined
for the patients whose samples were used in this study.
Patients with more than 12 months between two subsequent
visit samples were excluded from the analysis. Patient fol-
low-up periods ranged from 12 to 24 months. The P value
for the correlation between the CAP/CTM v2.0-measured
value and therapy failure as evidenced by CAP/CA v1.5 was
calculated using Fisher’s exact test and a 5-cp/ml moving
lower limit (Fig. 3). For limits of 20 to 45 cp/ml as deter-
mined with CAP/CTM v2.0, no statistically significant (P 
0.05) discrimination of patients below the moving lower
limit or above the moving lower limit with respect to treat-
ment failure was observed. However, for limits of 50 cp/ml
or higher, patients with levels above the threshold showed
significantly (P  0.05) higher rates of therapy failure than
the subthreshold group. Five percent of the patients with
viral loads below 50 cp/ml as determined with CAP/CTM
v2.0 experienced therapy failure, while patients with viral
loads above 50 cp/ml had an 11% rate of therapy failure.
Limits of 100 cp/ml or higher were not considered, since
limited group size did not allow for valid conclusions. No
correlation between positivity or height of viral load as mea-
sured with CAP/CTM v2.0 and use of protease inhibitors or
nonnucleoside reverse transcriptase inhibitors could be ob-
served (Student t test; P 	 0.2077).
We next tested the potential cross-reactivity of CAP/CTM
v2.0 with HIV-2 (Fig. 4). Plasma samples from six HIV-2-
seropositive individuals with viral loads above 1,000 cp/ml were
selected. All six individuals were HIV-1 seronegative during a
FIG. 2. Viral loads as measured with CAP/CTM v2.0 for samples
from HIV-1-infected patients under antiretroviral therapy that were
below the limit of quantification (50 cp/ml) as determined by CAP/CA
v1.5, plotted against the numbers of months that the patients showed
levels below the limit of quantification for CAP/CA v1.5. Samples with
viral loads between 20 and 50 cp/ml as determined by CAP/CTM v2.0
are not plotted.
FIG. 3. Probability of treatment failure for patients showing levels
below the threshold of quantification for CAP/CA v1.5 who were
retested with CAP/CTM v2.0. A 5-cp/ml moving lower limit was set,
and the probability of therapy failure for patients with levels below this
lower limit was compared to that for patients with levels above this
limit and was tested for significance. The figure shows the P values for
each limit (P  0.05 is significant).
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complete follow-up of more than 5 years, excluding a mixed
infection with HIV-1 and HIV-2. Four samples showed cross-
reactivity with CAP/CA v1.5, and two samples were negative.
None of the six samples generated a positive result with CAP/
CTM v2.0, indicating an improved HIV-1 specificity for this
test relative to that of CAP/CA v1.5.
Performance of CAP/CTM v1.0 and CAP/CTM v2.0 was
also tested against the WHO 1st international reference geno-
type panel (01/466) (Fig. 5). Data of the Abbott assay were
previously generated in our laboratory and were also described
in the work of Schutten et al. (18). All assays showed excellent
performance for group M samples of the reference panel
except CAP/CTM v1.0, which slightly underquantified the
CRF-02 sample. The group N sample was correctly quantified
by CAP/CTM v2.0 and the Abbott assay, slightly underquan-
tified by CAP/CA v1.5, and not quantified by CAP/CTM v1.0.
The group O sample was quantified only by CAP/CTM v2.0
and the Abbott assay. Data on the group O sample could not
be generated for CAP/CTM v1.0, due to the limited availability
of this panel member. It has previously been described, how-
ever, that CAP/CTM v1.0 does not detect HIV-1 group O (7).
Platform comparison. Five hundred clinical samples with
CAP/CA v1.5-measured viral loads of 500 cp/ml were 10-fold
diluted with HIV-1-seronegative and RNA-negative EDTA
plasma, aliquoted, and stored at80°C until tested with CAP/CA
v1.5, CAP/CTM v1.0, and CAP/CTM v2.0. A random selection of
297 samples was also tested with the Abbott assay. The subtype
distribution was as follows: 72 samples were of subtype A (66
A1 and 6 A2), 156 samples were of subtype B, 22 samples were
of subtype C, 7 samples were of subtype D, 4 samples were of
subtype F, 31 samples were of subtype G, 2 samples were of
subtype H, 1 sample was of subtype J, 1 sample was of subtype K,
and 1 sample was of an unknown subtype. In addition, three
samples known to be underquantified by CAP/CTM v1.0 were
also tested with the Abbott assay. These three samples were of
subtype C.
For the platform comparison, a regression analysis was per-
formed on data plots generated similarly to Bland-Altman
plots (plotting the mean of results from the two assays against
the difference between results from the two assays) (Fig. 6A to
C). The average viral loads for the CAP/CA v1.5, CAP/CTM
v1.0, CAP/CTM v2.0, and Abbott tests were 3.55 log10, 3.51
log10, 3.75 log10, and 3.70 log10, respectively. The slopes of the
regression curves were close to 0, 0.06, 0.02, and 0.00 for
comparison of the CAP/CTM v2.0 with CAP/CA v1.5, CAP/
CTM 1.0, and Abbott RealTime tests, respectively. The y in-
tercepts were slightly higher than 0 for all three comparisons
(0.41, 0.28, and 0.10 for the CAP/CA v1.5, CAP/CTM v1.0, and
Abbott tests, respectively), and the regression coefficients were
very low (0.02, 0.002, and 0.00004 for the CAP/CA v1.5, CAP/
CTM v1.0, and Abbott tests, respectively). The number of
samples underquantified by more than 1 log10 with CAP/CTM
2.0 relative to the results for CAP/CA v1.5 (1 [0.2%]) and
CAP/CTM v1.0 (0 [0%]) was significantly lower than the num-
ber of samples underquantified by these assays relative to the
results for CAP/CTM v2.0 (8 [1.6%] and 6 [1.2%], respec-
tively). Three samples (1%) were underquantified by the Ab-
bott assay by more than 1 log10 relative to the results for
CAP/CTM v2.0, versus one (0.3%) for the reverse situation.
DISCUSSION
In the present paper, the performance of the new Roche
dual-target CAP/CTM HIV-1 test, version 2.0, is described.
We show that the assay is HIV-1 specific and correctly quan-
tifies samples of HIV-1 groups M, N, and O. The viral loads
determined with CAP/CTM v2.0 for samples having HIV-1
RNA levels below the threshold of quantification for CAP/CA
v1.5 proved to be HIV-1 specific and correlated with therapy
failure. In addition, we could show that in patients under ther-
apy, viral load decreased over time until 31 months after ini-
tiation of therapy and that levels below 250 cp/ml could regu-
larly be detected with CAP/CTM v2.0 even 100 months after
initiation of therapy.
It has previously been reported that CAP/CTM v1.0 identi-
fied a significant proportion of samples with levels below the
threshold of quantification for CAP/CA v1.5 as HIV-1 positive,
FIG. 5. Viral loads for the WHO 1st reference panel as determined
by CAP/CTM v1.0, CAP/CTM v2.0, and the Abbott assay. N.T., not
tested.
FIG. 4. Viral loads of samples from six HIV-1-seronegative but
HIV-2-seropositive patients, measured with an in-house-developed
HIV-2 real-time quantitative RT-PCR assay, CAP/CTM v2.0, and
CAP/CA v1.5, are plotted.
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with viral loads well over 50 cp/ml. We have previously shown
that lack of an UNG system in real-time viral load measure-
ment may pose a significant problem for laboratories that used
to measure HCV RNA with CA v1.5 and switch to the use of
the Abbott real-time HCV assay, which has no UNG contam-
ination control system built in to its reaction (20). In the
present paper, we demonstrate that the UNG system of CAP/
CTM v1.0 and v2.0 is as efficient as the CAP/CA v1.5 UNG
system in elimination of dUTP-positive amplicons derived
from CAP/CA v1.5. We conclude that low HIV-1 RNA-posi-
tive values determined with CAP/CTM v2.0 for samples having
HIV-1 RNA levels below the threshold of quantification for
CAP/CA v1.5 are true positives. This conclusion was substan-
tiated by the observation that none of the HIV-1-seronegative
plasma replicates in the checkerboard analysis was above the
lower limit of detection for CAP/CTM v2.0. However, the
nature of the low viral titers in treated patients still needs to be
resolved. Release of virus particles from latently infected cells
or active virus replication could be the cause. We assume that
release of virus particles from a decaying pool of latently in-
fected cells is the cause for the long-lasting low viral load in
patients under therapy. This assumption is further supported
by the observation that in patients whose levels were below the
threshold of quantification for CAP/CA v1.5 (50 cp/ml) but
who tested HIV-1 positive with CAP/CTM v2.0, viral load
steadily declined during the first 31 months after initiation of
therapy and reached a plateau thereafter. The high sensitivity
and linearity of CAP/CTM v2.0 at the lower end of quantifi-
cation (50 cp/ml) compared to the levels for other HIV-1
viral load assays raises some critical questions for current na-
tional and international guidelines for treatment and for clin-
ical trials. Our data show that in each stratum (12, 12 to 24,
24 to 36, 36 to 48, and 48 months after initiation of therapy),
about 20% of patients would be reported as experiencing ther-
apy failure with CAP/CTM v2.0 while being reported as ther-
apy responders with CAP/CA v1.5. In our cross-sectional ret-
rospective data set, a viral load determined by CAP/CTM v2.0
to be above the threshold of quantification for CAP/CA v1.5
was statistically correlated with therapy failure, which suggests
that CAP/CTM v2.0 results at the low end have clinical impact.
The probability of virological failure in our hospital setting is
between 10 and 20%. The therapy failure rate of 11% for viral
loads above 50 cp/ml as determined by CAP/CTM v2.0 seems
clinically relevant, given that this rate is more than 2-fold
higher than that observed for the remaining patients with levels
below the threshold of quantification for CAP/CA v1.5. Pro-
spective longitudinal data sets are required, however, for new
cutoff values for clinical intervention based on CAP/CTM v2.0
to be defined.
Reliable quantification of subgroup M, including non-B
HIV-1 subtypes, is generally considered an important feature
of state-of-the-art HIV-1 quantification assays. Non-group-M
HIV-1 subgroups N and O are considered to be of minor
clinical importance due to the low numbers of infected indi-
viduals worldwide. A platform comparison and specificity study
using the WHO first reference panel for HIV-1 genotypes was
performed with Roche CAP/CA v1.5, CAP/CTM v1.0, and
CAP/CTM v2.0 and the Abbott assay. Overall, the platform
comparison based on mean titers, Bland-Altman analysis, and
the percentage of single strongly deviating measurements
FIG. 6. Regression plots of Bland-Altman analysis-derived data for
CAP/CTM v2.0 compared with results for CAP/CA v1.5 (A), CAP/
CTM v1.0 (B), and the Abbot M2000 system (C). Viral loads measured
were log10 transformed before analysis. Dashed lines indicate 1-log10
difference from the regression curve.
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shows that there are small quantitation differences between
CAP/CTM v2.0 and both CAP/CA v1.5 and CAP/CTM v1.0.
These differences are due to (i) titer shifts for individual mea-
surements (e.g., outliers seen in the plots) and (ii) smaller
quantitation differences concentrated at the medium and lower
assay range seen by the nonzero y intercepts and slopes (Fig.
6A and B). This indicates that CAP/CTM v2.0 measures higher
target concentrations in samples with medium-to-low viral
loads than the two predecessor tests. When the Abbott Real-
Time test was compared to CAP/CTM v2.0, fewer titer shifts of
individual measurements and only negligible differences over
the assay range were observed.
Due to the relatively low sequence homology between
HIV-1 and HIV-2, development of a viral load assay that is
able to reliably quantify all subtypes of both viruses is virtually
impossible. However, cross-reactivity may occur, as observed
with CAP/CA v1.5 in four out of the six HIV-2 plasma samples,
and could lead to misdiagnosis and inappropriate patient man-
agement. We were able to show that HIV-2 cross-reactivity of
CAP/CA v1.5 is probably solved with CAP/CTM v2.0, but
larger numbers of HIV-2-infected individuals need to be tested
for this question to be answered.
In conclusion, CAP/CTM v2.0 is, on the basis of the data
presented, an accurate and reliable test for HIV-1 viral load
measurement relative to the other assays used with respect to
specificity, sensitivity, and genotype inclusivity. It can be used
for high- and medium-throughput laboratories with low-qual-
ification personnel. The specificity and sensitivity of CAP/CTM
v2.0 are good relative to those observed for the other assays
used. Although our data suggest that low positive values as
determined with CAP/CTM v2.0 for patients under therapy are
correlated with therapy failure, additional clinical studies are
required for new cutoffs for therapy decisions and patient
management to be defined.
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